GLP-1 receptor agonist

16 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function

This study evaluates the clinical benefits of semaglutide, a GLP-1 receptor agonist, as an add-on therapy to insulin in patients with LADA, demonstrating improved glycemic control, BMI reduction, and insulin dose sparing, especially in thos

Section: Diabetes & EndocrinologyJun 27, 2026

GLP-1 receptor agonist

Latest news

Semaglutide as an Effective Add-On Therapy in Latent Autoimmune Diabetes in Adults: Enhancing Glycemic Control and Preserving β-Cell Function

Semaglutide and Neovascular Age-Related Macular Degeneration Among Adults with Type 2 Diabetes: An OHDSI Network Study

GLP-1 Receptor Agonist Use Linked to Lower Risk of Brain Aneurysm Rupture and Less Severe Bleeding

Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive Disorder

Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes

Orforglipron in Type 2 Diabetes and Obesity: A Promising Oral GLP‑1 Agonist That Delivers Clinically Meaningful Weight and Glycaemic Benefits

Increased Gestational Weight Gain and Adverse Pregnancy Outcomes After Stopping GLP‑1 Receptor Agonists Prior to or in Early Pregnancy

Targeting Mitochondria: A Practical Algorithm for Diabetes Care in Maternally Inherited Diabetes and Deafness (MIDD)

Tirzepatide Shows Promising Efficacy and Safety in Managing Youth-Onset Type 2 Diabetes: Insights from the SURPASS-PEDS Trial

Orforglipron: A Promising Oral GLP-1 Receptor Agonist for Long-Term Obesity Management

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

Amycretin: A Promising First-in-Class Dual GLP-1 and Amylin Receptor Agonist for Overweight and Obesity

Advancing Obesity Management: Once-Monthly Maridebart Cafraglutide Demonstrates Significant Weight Loss Efficacy

Efficacy and Safety of Ecnoglutide, a cAMP-Biased GLP-1 Receptor Agonist, in Weight Management for Overweight and Obese Adults: Insights from a Phase 3 Multicentre Randomised Trial